ipl-logo

Sanofi Pasteur: The Dengue Vaccine

757 Words4 Pages

SANOFI PASTEUR – THE DENGUE VACCINE DILEMMA
The case is regarding the company which developed the vaccine for the protection of Dengue. As per the claim of the company that it does not only deal with the Dengue Vaccine but it is the Dengue itself and the company is in fact dealing with the public health in the larger interest of the public. With the development of the vaccine to control that Dengue Fever it was the company’s biggest achievement but the result of the trial of the vaccine was 30% which is far below than the claim of the company which was 70% as after the issues which were found in the trial report the company had to work out the ways to overcome the problems to make the trial success.
Sanofi Pasteur is one of the biggest pharmaceutical …show more content…

By this time the firm was amongst the top 20 biggest pharmaceutical companies of the world. Subsidiary specific to vaccine development was formed in 2004 and was named as Sanofi Pasteur. Chris Viehbacher appointed as the CEO of the company on 1 December 2008. The individual also served in the famous pharmaceutical firm like Glaxo Smith Kline. The main focus of the company remained the health issues of the public keeping in view the needs of the patients. The strategy of the company was for the external partnership rather than development of medical products. Almost 50% of the productions of the products were halted by then. It was interesting to break the record and earn the income of $7.5 billion in 2009. The net income was 16% higher than the last year income of 2008. In 2009, almost 33 companies got merger with the Sanofi Pasteur which expanded the target audience and portfolio of the firm ranging from biotechnology, generics, public health and animal …show more content…

The firm bought major stakes in Indian’s pharmaceutical firm Shantha Biotechnics and added new vaccines development on its inventory. Their struggle in the vaccines development kept on increasing and the firm acquired VaxDesign, Florida based firm for the human responses to vaccines. On 6 May 2011 the company named it self as Sanofi.
Sanofi opened up its outlets in more than 40 countries with employing over 110,000 workers by 2011. The scope of the business was limited to Pharmaceuticals, development of vaccines and vetenary health. Its headquarters established in Paris.
With regards to the company’s dedicated division for the development of vaccines, there are many names which are connected to the company’s profile, starting from the famous microbiologist Louis Pasteur till Bacteriologist Dr Richard Slee and many more. All the scientists in the division were destined for the single cause that is to save the humanity fro the infectious diseases.
In 2011, Olivier Charmail was appointed as the executive vice president of the vaccines division. Annual sale of the company reached $4.5 billion with over 12000 employees. Same year the company claimed that it saved the lives of approximately 500 million people with the help of over 1 billion vaccine

Show More
Related

  • H-E-B Background

    552 Words  | 3 Pages

    Within this moment H-E-B has around 85,000 Employees and an estimated amount of 2.2 billion in annual

    Read More

  • Jim Valvano Never Give Up

    723 Words  | 3 Pages

    The foundation has now raised over 150 million dollars due to the fact that it is one of the most well known

    Read More

  • Informative Speech On St. Jude Research Hospital

    906 Words  | 4 Pages

    In the early 2000’s St. Jude began to expand more in staff cures and new patients. The C.E.Os. of St. Jude are Dr. Donald Pinkel (1961-1973) he was the first director and ceo of St. Jude he focused most of his time of the frequent cancer in children, he and his colleges used most of their time trying to find cures for cancer. Dr. James R. Downing is the 6th and current ceo and director of St. Jude. He works a s a Genome sequencing pioneer, and over sees the Pediatric Cancer Genome Project.

    Read More

  • I Will Not Be Pinkwashed Analysis

    1615 Words  | 7 Pages

    (Benfit) She further explains how much Susan G. Koman “for the cure”(Benfit) is a multi million dollar company, totaling over $390 million dollars. Stating only 20.9% of the money actually goes to research in helping to find a cure. By then asking, “Where does the money go?” and showing a chart of the Komen’s 2009-2010 year expenses.

    Read More

  • How Did Jonas Salk Conquering Polio

    1655 Words  | 7 Pages

    Jonas Salk was an American physician, immunologist and a virologist, someone who studies viruses. He set some goals for himself: “To establish an institute that would explore questions about the basic principles in life,” and “to make it possible for biologists and others to work together in a collaborative environment that would encourage them to consider the wider implications of their discoveries for the future of humanities (www.salk.edu).” Because of his goal, that he clearly stated, Salk became referred to as the “Father of Biophilosophy.” He was also named as the “Father of Biophilosophy” because he also didn’t patent his vaccine. Salk would have been richer by $7 billion if his vaccine were patented. (www.forbes.com)

    Read More

  • St. Jude Cancer Research Essay

    476 Words  | 2 Pages

    That is $1,500,000. St.Jude’s even treats around the world. There is only one St.Jude’s with a maximum capacity of 7,800 which is full right now. Being able to treat many from other countries is very limited but they try their very best. Without all the generous donations received, St.Jude’s would be very

    Read More

  • Compare Martin Luther King Jr Salk

    426 Words  | 2 Pages

    I've always admired Martin Luther King Jr. Early in life, I learned that he fought for the rights of, not only me but, my friends and family. Life in the America wasn't always like it is now. At a young age I understood how he transformed the landscape of America and gave more meaning to the term “equality”. He benefited society in unimaginable ways.

    Read More

  • Hrm 531 Week 3 Team Assignment

    516 Words  | 3 Pages

    West Pharmaceutical Services peaks my interest as they do work in the form research and development of medicine delivery systems. They have had years to refine the company from its start in 1923 as it has transitioned from research lab packing penicillin to groundbreaking biomedical product production and testing. I am interested in this company as the various research done at their facilities can supplement my knowledge on the working of various devices within the biomedical industry. Moreover, the company is large enough to allow for personal growth within the company to a high extent as I may grow as a biomedical engineer. I would like to contribute to West’s reliability in creating high-quality and technologically advanced containment and delivery solutions.

    Read More

  • Case Study Global Product Roll Out

    1051 Words  | 5 Pages

    They didn’t want to lose out on any profits by going global. Since they were new to this line of business they partner with J&J’s McNeil division. J&J were an excellent choice to partner with to introduce Benecol to the global market. The only hurdles stopping Benecol to be introduced into the world were regulatory issues. It would be difficult to bring Benecol to the market as quickly as possible in Europe and even more so in US.

    Read More

  • Johnson & Johnson Value Chain Analysis Summary

    942 Words  | 4 Pages

    Johnson & Johnson currently has a 10.4% market share of the Pharmaceutical Manufacturing industry. They have the second largest share of this industry, just behind Amgen at 10.9%. By looking at the revenue and operating income for Johnson & Johnson, we can see their margins and evaluate their performance. Johnson & Johnson’s operating profit margin improved from 2015 to 2016 but decreased significantly from 2016 to 2017. The operating profit margin for the company as a whole in 2016 was 28.72% and in 2017 it was 24.07% (Appendix A).

    Read More

  • Benefits Of Mandatory Vaccination

    1557 Words  | 7 Pages

    Disease can overthrow a culture and spread like wildfire when not taken precaution against. However, there exists a fierce opposition against the mandate of vaccination by some groups of interest with the existence of adverse effects by vaccination to the human body as a reason. Although vaccination carries some health risks,

    Read More

  • Porter's Five Forces In The Pharmacy Industry

    1156 Words  | 5 Pages

    The number of acquisitions is not so high and it depends more upon the organic expansion. • These pharmacies face informative and predictable risk from the variability of “generic conversion” • Inability of the company to keep stride with the growing private labeled brands popularity. • The in-store implementation of the store formats and services is not consistent at every

    Read More

  • Porter's Five Forces Analysis Pharmaceutical Industry

    720 Words  | 3 Pages

    Many new companies to enter the market without burden of costly tasks such as research and development, clinical trials and manufacturing of drugs. Moreover, patent expiry is one of the reasons which is offering opportunities for lower cost generic manufacturer in terms of greater market access. Additionally, the government has increased their focus on healthcare cost cutting. It is creating pressure on the authority to allow early introduction of low-cost drugs in the

    Read More

  • Case Study: Janssen Pharmaceutica '

    1472 Words  | 6 Pages

    There is large investments being made in new technology to reduce production times and improve quality so that patients receive the best quality products in the swiftest manner. Patient care is at the heart of Janssen as clinical trials are on site to always try to gain more information on the potential products to improve. Janssen is a subsidiary of Johnson & Johnson, so to look at the organisation structure it must fall under J&J’s structure first. J&J’s organisation can be split into three main factions; Consumer healthcare, medical devices and pharmaceuticals.

    Read More

  • Rorer Converts-Poulenc Case Study

    2104 Words  | 9 Pages

    INTRODUCTION The latter decade of the 20th century brought a number of major innovations to the pharmaceutical industry, most notably a remarkable wave of successful joint ventures and mergers between big and medium players in the market. In this case study we analyzed the Rorer and Rhône-Poulenc (RP) merger in July 31, 1990 that created a major multinational company: the Rhône-Poulenc Rorer, Inc. (RPR), where the RP became the majority shareholder, owning 68 percent of the RPR’s shares. Prior to the merger, Rorer lacked the resources to access the European market, and the firm presented relatively low cash balance and rising debt which, according to financial analysts, appeared to be handicapping its strategy of growth by acquisitions.

    Read More

More about Sanofi Pasteur: The Dengue Vaccine

Open Document